Am­gen swoops in with $13.4B deal to pluck block­buster Ote­zla from Cel­gene

Now that their En­brel fran­chise ap­pears to be se­cure from copy­cat in­ter­lop­ers, Am­gen is go­ing for a sure thing on the deal side to bol­ster its rev­enue pro­jec­tions.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.